List of Hetlioz drug patents

Hetlioz is owned by Vanda Pharms Inc.

Hetlioz contains Tasimelteon.

Hetlioz has a total of 20 drug patents out of which 1 drug patent has expired.

Expired drug patents of Hetlioz are:

  • US5856529

Hetlioz was authorised for market use on 31 January, 2014.

Hetlioz is available in capsule;oral dosage forms.

Hetlioz can be used as treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food, treatment of non-24 hour sleep-wake disorder by administering tasimelteon; treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon, treatment of non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors, treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; treatment of non-24 hour sleep-wake disorder by administering tasimelteon to patients with a smoking history, treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with rifampin; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin, treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food, treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor, treatment of non-24 hour sleep-wake disorder by administering tasimelteon, treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime, treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon, treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists, treatment of non-24-hour sleep-wake disorder, treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor.

The generics of Hetlioz are possible to be released after 29 August, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(a month ago)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855241 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

USRE46604 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

US9060995 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

US10449176 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

US10945988 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

US9549913 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(10 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(11 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(11 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(11 years from now)

US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(12 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(12 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24 hour sleep-wake disorder by administering tasimelteon; Treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime; Treatment of non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; Treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of non-24 hour sleep-wake disorder by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of non-24-hour sleep-wake disorder; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon

Dosage: CAPSULE;ORAL

How can I launch a generic of HETLIOZ before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic